Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials

Data de publicação: 01/08/2022 Data Ahead of Print: 01/05/2022

Autores da FMUP

• Francisco Aguiar Vasques Novoa Faria

  Autor

• Marta Borges Canha

  Autor

• Joaquim Adelino Correia Ferreira Leite Moreira

  Autor

• João Sérgio De Lima Soares Neves

  Autor

• João Pedro Melo Marques Pinho Ferreira

  Autor

Participantes de fora da FMUP

• Leite, AR
• Angelico Goncalves, A

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

Our aim was to study the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on the risk of any cardiovascular event in adults with overweight or obesity and without diabetes. We conducted a random-effects meta-analysis of placebo-controlled randomized controlled trials. Nine trials were eligible and, in total, 11 430 patients were included, of which 7702 (67%) were submitted to treatment with GLP-1 RA. During follow-up, 673 participants receiving GLP-1 RA treatment (8.7%) and 416 participants receiving placebo (11.2%) had a cardiovascular event. Treatment with GLP-1 RA versus placebo resulted in a reduction in the risk of any cardiovascular event (RR = 0.81, CI 0.70-0.92; p = .001). In overweight or obese adults without diabetes, treatment with GLP-1 RA reduced the risk of cardiovascular events. Our findings support the use of GLP-1 RA for reducing the cardiovascular risk of these patients.

© 2022 John Wiley & Sons Ltd.

Keywords

• Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Obesity; Overweight; Randomized Controlled Trials as Topic; glucagon like peptide 1 receptor agonist; liraglutide; placebo; semaglutide; antidiabetic agent; glucagon like peptide 1; glucagon like peptide 1 receptor; cardiovascular disease; cardiovascular mortality; cardiovascular risk; cerebrovascular accident; clinical outcome; diabetes mellitus; disease association; drug effect; follow up; heart infarction; heart muscle ischemia; human; Letter; meta analysis; obesity; randomized controlled trial (topic); risk reduction; adult; cardiovascular disease; complication; non insulin dependent diabetes mellitus; obesity